Navigation Links
Kewaunee Scientific Reports Improved Results for Third Quarter

STATESVILLE, N.C., Feb. 26, 2013 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported sales and earnings for its third quarter ended January 31, 2013.

Sales for the quarter were $27,450,000, up 27% from sales of $21,574,000 in the third quarter last year. Net earnings for the quarter were $544,000, or $0.21 per diluted share, as compared to a net loss of $122,000, or $0.05 per diluted share, in the third quarter last year. Earnings for the quarter were favorably impacted by the increase in sales, continued strong results from International operations, and reduced manufacturing, overhead, and administrative costs. The order backlog was $84.5 million at January 31, 2013, up from $77.1 million at January 31, 2012.

Domestic sales for the quarter were $20,445,000, up 19% from sales of $17,142,000 in the third quarter last year. The Company continues to make excellent progress in winning projects through its strengthened dealer network. The marketplace for privately-funded projects continued to hold up relatively well during the quarter, while opportunities for publicly-funded wood educational projects remained well below pre-recession levels, as state and local governments continued to receive significantly lower funding for capital projects.

International sales for the quarter were $7,005,000, up 58% from sales of $4,432,000 in the third quarter last year. The Company has a strong backlog of international orders and continues to see increased opportunities for sales and orders in the growing Asia and Middle East laboratory markets.

Sales for the nine months ended January 31, 2013 were $85,318,000, up 16% over sales of $73,857,000, in the comparable period last year.  Domestic sales were $68,757,000, up 7% over sales of $64,364,000 in the same period last year.  International sales were $16,561,000, up 74% from sales of $9,493,000 in the same period last year. Net earnings for the nine months ended January 31, 2013 were $1,827,000, or $0.71 per diluted share, as compared to a net loss of $225,000, or $0.09 per diluted share, in the comparable period last year.

The Company's balance sheet continues to be strong. Cash on hand was $4.9 million at the end of the quarter, as compared to $4.6 million at January 31, 2012.  Working capital was $24.3 million, as compared to $21.5 million at the end of the same period last year. Short-term borrowings under the Company's $15 million bank line of credit were $2.7 million, as compared to $6.4 million at January 31, 2012. Total bank borrowings and capital lease obligations were $6.2 million, as compared to $10.2 million at the end of the third quarter last year, and the debt-to-equity ratio was .20-to-1, as compared to .34-to-1.

"We continued to make excellent progress during the quarter," said William A. Shumaker, Kewaunee's Chief Executive Officer. "I am pleased with sales and earnings, particularly since the third quarter is historically our slowest due to normal construction cycles and the large number of holidays. We continue to see positive results from our strengthened domestic dealer network and our broadened international dealer network. When combined with our lower manufacturing costs, this is providing us with more opportunities to close orders in both of these geographic markets.

"Looking forward, we expect to have a strong finish to our year. Incoming orders and customer delivery requirements for our metal furniture, fume hoods, and epoxy resin products have provided us a strong backlog of orders scheduled to ship in the fourth quarter. This increased demand and our lower costs are expected to more than offset the continuing lower demand for publicly-funded wood educational projects. It should be mentioned that results for the fourth quarter of last year were unusually strong, as results were favorably impacted by several large international projects that were manufactured and shipped during the quarter."

Kewaunee Scientific Corporation is a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Laboratory furniture products include both steel and wood cabinetry, fume hoods, adaptable modular systems, moveable workstations, biological safety cabinets, and epoxy resin counters and sinks. Healthcare furniture products include laminate casework, storage systems, and related products for healthcare applications. Technical furniture products include column systems, slotted-post systems, pedestal systems, and stand-alone benches.

The Company's corporate headquarters are located in Statesville, North Carolina. Three manufacturing facilities are located in Statesville, NC serving the domestic and international markets. One manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company has subsidiaries in Singapore and India. Kewaunee Scientific's website is located at

Certain statements in this release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, markets, products, services, and prices.

 Kewaunee Scientific CorporationConsolidated Statements of Operations (Unaudited)(in thousands, except per share data)Three months endedNine months ended January 31, January 31,2013201220132012Net sales$
73,857Cost of products sold22,44117,80369,83962,053Gross profit5,0093,77115,47911,804Operating expenses4,0543,99012,20511,950Operating earnings (loss)955(219)3,274(146)Other income84193260228Interest expense(80)(110)(295)(333)Earnings (loss) before income taxes959(136)3,239(251)Income tax expense (benefit)177(170)962(237)Net earnings (loss)782342,277(14)Less: net earnings attributable tothe noncontrolling interest238156450211Net earnings (loss) attributable to Kewaunee Scientific Corporation$
(225)Net earnings (loss) per share attributable toKewaunee Scientific Corporation stockholdersBasic$
(0.09)Weighted average number of common  shares outstandingBasic2,5902,5792,5862,579Diluted2,6042,5792,5962,579 Kewaunee Scientific CorporationCondensed Consolidated Balance Sheets(in thousands)January 31,April 30,20132012Assets(Unaudited)Cash and cash equivalents$
,188Restricted Cash692704Receivables, less allowances20,06423,244Inventories12,88811,760Prepaid expenses and other current assets2,2691,702Total Current Assets40,11543,598Net property, plant and equipment14,89015,346Other assets5,6185,192Total Assets$
4,136Liabilities and EquityShort-term borrowings$
,816Current obligations under capital leases and long-term debt200236Accounts payable8,5628,848Other current liabilities4,3604,340Total Current Liabilities15,82920,240Other non-current liabilities12,09512,238Total Liabilities27,92432,478Noncontrolling interest1,8452,147Kewaunee Scientific Corporation equity30,85429,511Total Equity32,69931,658Total Liabilities and Equity$


D. Michael Parker704/871-3290 

SOURCE Kewaunee Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
2. Kewaunee Scientific Corporation Declares Quarterly Dividend
3. Kewaunee Scientific Reports Record Sales for Second Quarter
4. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
5. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
6. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
7. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
8. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
9. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
10. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
11. Generex Augments Antigen Express Scientific Advisory Board
Post Your Comments:
(Date:11/27/2015)... NEW YORK , November 27, 2015 ... health system is set to go online. The potential ... and processes is vast and far from fully exploited ... access to patient health records, either via mobile tablet ... ) --> ) ...
(Date:11/27/2015)... , Nov. 27, 2015 Research and ... the "Global Intrauterine Devices Market 2015-2019" report ... --> In this report, the author the ... devices market for 2015-2019. To calculate the market size, ... following type of products: Hormonal IUDs and copper IUDs. ...
(Date:11/26/2015)... Países Bajos, November 26, 2015 ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... enfoque combina la inmunoterapia con la terapia fotodinámica de ... Clinical Cancer Research . --> Clinical Cancer ...
Breaking Medicine Technology:
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... ... 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively ... transitions to wipes with blur & drop shadow options. Utilize the controls in ... one clip to the next with TransPack's easily customizable styles. , TransPack ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... healthcare professionals worldwide today released the results of a survey of educational needs ... and Africa found a growing global demand for high quality online and face-to-face ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... to announce their strategic partnership at the Radiological Society of North America ... Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced their ...
(Date:11/30/2015)... ... November 30, 2015 , ... Several significant coding-related changes are ... likely to include new codes for spine and hip X-rays, paravertebral facet blocks ... of code changes in musculoskeletal, radiology and nervous system sections on an Orthopedic ...
Breaking Medicine News(10 mins):